Jeff T Hutchins

Inhalon Biopharma, Inc.

NIH Rank #1579
  • Top 10% Funded
  • Early Career

NIH Funding · FY2024

Total Funding
$4.1M
Fiscal year 2024
Grants Awarded
4
Active NIH grants
National Rank
#1,579
Among 57,894 PIs
First NIH Award
2024
Year of first funding

Funding & rank history

NIH funding totals and national rank by fiscal year.

Single fiscal year on record (FY2024): $4.1M across 4 grants · National rank #1579.

Top grants by award amount

Jeff T Hutchins's NIH grant portfolio, ranked by award amount.

  • 1R44AI177199-01A1R44
    SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections
    $1M
    award amount
  • 1R44AI181347-01A1R44
    IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection
    $1M
    award amount
  • 1R44AI186834-01R44
    Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV
    $1M
    award amount
  • 5SB1AI179368-02SB1
    GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
    $996.8K
    award amount

Affiliation

Institutions that have administered grants for Jeff T Hutchins.

Affiliated with Inhalon Biopharma, Inc. (NC).

Career milestones

Key NIH funding milestones over time.

  1. 2024
    First NIH Award
    Inhalon Biopharma, Inc.
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #1579
  6. 2024
    Entered Top 25% Nationally
    Ranked #1579
  7. 2024
    Entered Top 10% Nationally
    Ranked #1579